BioForm Announces Closing of IPO and Exercise of Underwriters' Over-Allotment Option

Thursday, November 15, 2007 General News J E 4
SAN MATEO, Calif., Nov. 14 BioForm Medical, Inc.(Nasdaq: BFRM) announced that on November 13, 2007, it closed its previouslyannounced initial public offering of 10,000,000 shares and that theunderwriters of the offering exercised their over-allotment option in full andpurchased 1,500,000 additional shares of common stock at the public offeringprice of $8.00 per share. Including the over-allotment, the company sold11,500,000 shares in the offering, resulting in net proceeds of approximately$83.4 million after deducting the underwriting discounts and commission andthe estimated offering expenses.

J.P. Morgan Securities Inc. and Piper Jaffray & Co. are serving as jointbook-running managers for the offering, with CIBC World Markets Corp. andJefferies & Company, Inc. serving as co-managers.

A registration statement relating to these securities has been filed with,and declared effective by, the U.S. Securities and Exchange Commission. Thispress release shall not constitute an offer to sell or the solicitation of anoffer to buy nor shall there be any sale of these securities in any state orjurisdiction in which such an offer, solicitation or sale would be unlawfulprior to registration or qualification under the securities laws of any suchstate or jurisdiction.

A copy of the final prospectus for the offering may be obtained from theprospectus department of either J.P. Morgan Securities Inc., 4 Chase MetrotechCenter, CS Level, Brooklyn, NY 11245, or by calling (718) 242-8002; or PiperJaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402 or bycalling (877) 371-5212.

About BioForm Medical, Inc.:

BioForm Medical, Inc. is a medical aesthetics company headquartered in SanMateo, California. BioForm's products include Radiesse(R), a long-lastingfiller for use in facial aesthetics and vocal fold insufficiency, andCoaptite(R) for treating female stress urinary incontinence which is marketedthrough a partnership with Boston Scientific Corporation.CONTACT: Adam Gridley 650/286-4025 Vice President, Corporate Development BioForm Medical, Inc.

SOURCE BioForm Medical, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Imagenetix, Inc. Reports Second Fiscal Quarter Res...
Chromos provides shareholder update